表紙
市場調查報告書

酪氨酸蛋白激酶 CSK:開發中產品分析

Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 365776
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
酪氨酸蛋白激酶 CSK:開發中產品分析 Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 85 Pages
簡介

本報告提供以酪氨酸蛋白激酶 CSK為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪氨酸蛋白激酶 CSK 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Advenchen Laboratories, LLC
  • Athenex, Inc.
  • Basilea Pharmaceutica AG
  • Pfizer Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2003TDB

Summary

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Respiratory and Toxicology which include indications Breast Cancer, Colon Cancer, High-Grade Glioma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Arrhythmias, Asthma, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Fallopian Tube Cancer, Fibrosarcoma, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leiomyosarcoma, Liposarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Psoriasis, Radiation Injury, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma, Renal Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • Advenchen Laboratories LLC
  • Athenex Inc
  • Pfizer Inc
  • Pulmatrix Inc
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles
  • apatinib mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bosutinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eCF-506 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KX-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PP-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PUR-1800 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit C Src Kinase for Colon Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CSK for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tirbanibulin mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • UM-164 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
  • Sep 29, 2019: Elevar announces results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-stage Gastric Cancer patients
  • Sep 11, 2019: Athenex announces initiation of phase I clinical study in china of KX2-36 oral by partner Guangzhou Xiangxue pharmaceutical
  • Aug 23, 2019: HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma
  • Aug 06, 2019: HLB to seek pre-NDA meeting with FDA for rivoceranib
  • Jun 27, 2019: LSK BioPharma announces preliminary review of top-line results from ANGEL Study
  • Jun 06, 2019: Athenex and PharmaEssentia announce positive early signals of clinical activity of KX2-391 (INN: tirbanibulin) in patients with Psoriasis
  • Apr 08, 2019: LSK BioPharma and Jiangsu Hengrui Medicine announce FDA clearance to initiate a phase 3 clinical trial in advanced Hepatocellular Carcinoma
  • Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
  • Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
  • Feb 12, 2019: LSKB Announces that the ANGEL Study Has Reached its Primary Completion Date
  • Feb 12, 2019: Pulmatrix receives US Patent for Inhaled Narrow Spectrum Kinase Inhibitor PUR1800
  • Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting
  • Oct 29, 2018: LSKB announces completion of enrollment for the ANGEL Study of Rivoceranib (Apatinib) in Gastric Cancer
  • Sep 17, 2018: Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Advenchen Laboratories LLC, H2 2019
  • Pipeline by Athenex Inc, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Pulmatrix Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top